For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

In World War II, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

The drugmaker is looking to its acute pain drug, Journavx, to drive growth beyond its established line of cystic fibrosis ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Vertex Pharmaceuticals Inc (VRTX) reports robust financial performance with significant revenue growth and strategic product ...

Vertex provided 2025 revenue guidance of $11.75 billion to $12 billion, reflecting 8% growth at the midpoint. Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...